Private Advisor Group LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 99,240 shares of the company’s stock, valued at approximately $114,827,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. TD Capital Management LLC increased its position in Eli Lilly and Company by 10.6% during the third quarter. TD Capital Management LLC now owns 73 shares of the company’s stock worth $85,000 after acquiring an additional 7 shares during the period. Integrity Financial Corp WA boosted its holdings in Eli Lilly and Company by 1.3% during the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock valued at $767,000 after purchasing an additional 8 shares in the last quarter. LCM Capital Management Inc grew its position in Eli Lilly and Company by 3.3% in the third quarter. LCM Capital Management Inc now owns 253 shares of the company’s stock valued at $293,000 after acquiring an additional 8 shares during the period. Smith Shellnut Wilson LLC ADV increased its holdings in shares of Eli Lilly and Company by 4.1% during the third quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company’s stock worth $235,000 after buying an additional 8 shares in the last quarter. Finally, Financial Network Wealth Advisors LLC raised its holdings in shares of Eli Lilly and Company by 5.6% in the third quarter. Financial Network Wealth Advisors LLC now owns 151 shares of the company’s stock valued at $175,000 after buying an additional 8 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities analysts have recently issued reports on LLY shares. Bank of America reissued a “buy” rating and issued a $1,497.00 price target on shares of Eli Lilly and Company in a report on Friday, October 30th. Cantor Fitzgerald increased their price target on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a research report on Monday, November 2nd. Argus upped their target price on shares of Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a report on Friday, October 30th. Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price on the stock in a report on Tuesday, September 15th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, October 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,422.00.
Eli Lilly and Company Price Performance
Shares of LLY stock opened at $1,380.92 on Thursday. The business has a fifty day simple moving average of $1,258.86 and a 200 day simple moving average of $1,115.99. The company has a market cap of $1.30 trillion, a P/E ratio of 44.82, a P/E/G ratio of 1.69 and a beta of 0.40. The company has a quick ratio of 1.00, a current ratio of 1.39 and a debt-to-equity ratio of 1.17. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,475.25.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business’s quarterly revenue was up 38.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $7.02 earnings per share. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is currently 22.46%.
Insider Activity at Eli Lilly and Company
In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.
Key Eli Lilly and Company News
Investors following LLY have been watching these news items:
- Positive Sentiment: Health Canada also approved Lilly’s GLP-1 pill for weight loss, adding a potential growth opportunity in the obesity market. Article: Health Canada approves Eli Lilly’s GLP-1 pill for weight loss
- Positive Sentiment: Lilly is expanding oncology research through its planned acquisition of Calytrix Bio, potentially worth up to $1.5 billion, and a Stipple Bio collaboration that could reach $5.9 billion. The deals add cancer programs and precision-therapy research, though much of their value depends on future milestones and development. Article: Eli Lilly expands its oncology research platform
- Negative Sentiment: State Street Health Care SPDR (XLV) sold its entire portfolio on Nov. 17, including $42.3 million of LLY shares. This is a reported fund outflow, although the fund sold all 60 holdings rather than singling out Lilly. Article: What State Street Health Care SPDR sold
Eli Lilly and Company Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
See Also
- Five stocks we like better than Eli Lilly and Company
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
